CORDIA Convention

The Company's research programs are focused on growing these businesses and on establishing new therapeutic areas, including oncology. Serono also has a network of alliances with other biotech companies and academic groups. Headquartered in Geneva the company has over 4,900 employees, operates in 44 countries with sales in over 90 countries and has a global manufacturing capability. In 2004, Serono achieved worldwide revenues of US$2,458.1 million, and a net income of US$494.2 million. Bearer shares of Serono S.A., the holding company, have been traded on the SWX Swiss Exchange (SEO) since 1987 and its American Depositary Shares were listed on the New York Stock Exchange (SRA) in July 2000. ( www.cordiaconvention.com )